Creative Biolabs performs strict anaerobic isolation and high-throughput screening to recover diverse R. gnavus strains from human or animal specimens. We combine selective media, colony picking, and phenotype-guided enrichment to build custom strain panels that capture mucin degradation, bile acid metabolism, and metabolite-secretion diversity for your program.
Our team applies polyphasic identification to R. gnavus isolates, integrating 16S rRNA profiling, whole-genome sequencing, and in silico comparative genomics. This enables clade-level resolution, detection of inflammatory capsular polysaccharide loci, bile acid–related pathways, and key carbohydrate-active enzymes that distinguish potentially harmful from potentially beneficial R. gnavus lineages.
Creative Biolabs characterizes R. gnavus carbohydrate fermentative profiles using defined glycan panels, including dietary fibers and host-derived substrates such as mucin O-glycans. We quantify growth kinetics, SCFA (particularly acetate and propionate) production, and glycan utilization patterns to link specific R. gnavus strains to host-relevant carbon sources and metabolic signatures.
Our functional and MoA screening assays map the mechanisms by which R. gnavus influences host biology. We integrate exopolysaccharide characterization, capsular polysaccharide profiling, transcriptomics, and metabolomics with immune and epithelial readouts to determine how different R. gnavus genotypes drive pro- or anti-inflammatory responses and impact barrier integrity and signaling pathways.
Creative Biolabs offers customized host–R. gnavus interaction assays using primary or immortalized epithelial cells, mucus-producing lines, and co-culture systems with immune cells. Readouts include barrier function, mucin expression, cytokine/chemokine profiles, and transcriptional responses to distinct R. gnavus strains, surface structures, or secreted metabolites under controlled anaerobic conditions.
We design in vitro immune assays to quantify how R. gnavus modulates dendritic cells, macrophages, and T-cell subsets. Using defined bacterial preparations and fractionated components, we evaluate cytokine signatures, Treg versus Th1/Th2/Th17 skewing, and pattern-recognition receptor engagement to explain contrasting immune phenotypes reported for distinct R. gnavus isolates.
Creative Biolabs runs scalable anaerobic fermentation for R. gnavus, from milliliter-scale feasibility studies to liter-scale production for in vivo models and advanced in vitro systems. Fermentation parameters, media composition, and feeding strategies are optimized per strain to ensure consistent biomass, defined metabolite profiles, and tight control of growth phase and viability.
Our biological safety testing assesses R. gnavus strains and preparations for key risk attributes relevant to microbiome research. Depending on project needs, panels can include antibiotic susceptibility profiling, toxin gene screening, genome safety annotation, contaminant monitoring, and stability assessments, generating robust datasets for internal governance and external review.
